Literature DB >> 23623902

B7-H4.Ig inhibits the development of type 1 diabetes by regulating Th17 cells in NOD mice.

I-Fang Lee1, Xiaojie Wang, Jianqiang Hao, Noushin Akhoundsadegh, Lieping Chen, Linda Liu, Sol Langermann, Dawei Ou, Garth L Warnock.   

Abstract

Type 1 diabetes (T1D) is an autoimmune disease characterized by immunological destruction of insulin-producing pancreatic β-cells and subsequent hyperglycemia. The non-obese diabetic (NOD) mouse strain spontaneously develops a disease similar to human T1D and is commonly used as an animal model for studying this disease. We have previously shown that the administration of B7-H4-immunoglobulin fusion protein (B7-H4.Ig), a newly identified T-cell co-inhibitory signaling molecule, blocks the onset of diabetes in NOD mice. However, the mechanism(s) by which B7-H4 protects NOD mice from T1D is not fully understood. IL-17 is a pro-inflammatory cytokine, produced by Th17 cells, that activates T cells and other immune cells to produce a variety of cytokines and chemokines. Increasing evidence has shown that therapeutic agents targeting the IL-17 molecule or directly inhibiting IL-17-producing cells regulate autoimmune diabetes in NOD mice, suggesting that IL-17 is involved in the pathogenesis of this disease. In this study, we investigate whether B7-H4.Ig treatment inhibits the generation of Th17 cells which subsequently decreases IL-17 production and prevents the onset of T1D in NOD mice. Pre-diabetic female NOD mice were injected intraperitoneally with control mouse IgG or B7-H4.Ig starting at 4 weeks of age for 12 weeks. Our data showed that the frequency of Th17 cells in B7-H4.Ig-treated mice was significantly decreased. In addition, our data showed that B7-H4.Ig-treated mice had decreased levels of pro-inflammatory cytokines and Th17-associated cytokines, and an increased level of the potent Th17 inhibitor IFN-γ. To further investigate the effect of B7-H4.Ig on differentiation of Th17 cells, we co-cultured splenocytes with Th17-polarizing cytokines in the absence or presence of B7-H4.Ig. Our results indicated that splenocytes, under the Th17 driving conditions in the presence of B7-H4.Ig, had significantly decreased the numbers of Th17 cells compared to cells co-cultured in the absence of B7-H4.Ig. Together, this study suggests that blocking the generation of Th17 cells with the administration of B7-H4.Ig effectively inhibits the development of T1D in NOD mice.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23623902     DOI: 10.1016/j.cellimm.2013.03.005

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  15 in total

Review 1.  Helicobacter pylori Deregulates T and B Cell Signaling to Trigger Immune Evasion.

Authors:  Victor E Reyes; Alex G Peniche
Journal:  Curr Top Microbiol Immunol       Date:  2019       Impact factor: 4.291

2.  Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality.

Authors:  Asim Saha; Patricia A Taylor; Christopher J Lees; Angela Panoskaltsis-Mortari; Mark J Osborn; Colby J Feser; Govindarajan Thangavelu; Wolfgang Melchinger; Yosef Refaeli; Geoffrey R Hill; David H Munn; William J Murphy; Jonathan S Serody; Ivan Maillard; Katharina Kreymborg; Marcel van den Brink; Chen Dong; Shuyu Huang; Xingxing Zang; James P Allison; Robert Zeiser; Bruce R Blazar
Journal:  JCI Insight       Date:  2019-10-03

Review 3.  Potential targeting of B7-H4 for the treatment of cancer.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 4.  The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.

Authors:  Murali Janakiram; Urvi A Shah; Weifeng Liu; Aimin Zhao; Mark P Schoenberg; Xingxing Zang
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 5.  B7-H4 as a protective shield for pancreatic islet beta cells.

Authors:  Annika C Sun; Dawei Ou; Dan S Luciani; Garth L Warnock
Journal:  World J Diabetes       Date:  2014-12-15

6.  B7x/B7-H4 modulates the adaptive immune response and ameliorates renal injury in antibody-mediated nephritis.

Authors:  R D Pawar; B Goilav; Y Xia; L Herlitz; J Doerner; S Chalmers; K Ghosh; X Zang; C Putterman
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

7.  B7-H4 Modulates Regulatory CD4+ T Cell Induction and Function via Ligation of a Semaphorin 3a/Plexin A4/Neuropilin-1 Complex.

Authors:  Joseph R Podojil; Ming-Yi Chiang; Igal Ifergan; Ronald Copeland; Linda N Liu; Sebastien Maloveste; Solomon Langermann; David Liebenson; Roumen Balabanov; Hongbo Chi; Lieping Chen; Dario A A Vignali; Stephen D Miller
Journal:  J Immunol       Date:  2018-06-13       Impact factor: 5.422

Review 8.  The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial.

Authors:  Peter John; Yao Wei; Weifeng Liu; Meirong Du; Fangxia Guan; Xingxing Zang
Journal:  Trends Pharmacol Sci       Date:  2019-10-31       Impact factor: 14.819

Review 9.  Novel Immune Check-Point Regulators in Tolerance Maintenance.

Authors:  Yanxia Guo; Adele Y Wang
Journal:  Front Immunol       Date:  2015-08-18       Impact factor: 7.561

Review 10.  Advances in the cellular immunological pathogenesis of type 1 diabetes.

Authors:  Min Li; Lu-Jun Song; Xin-Yu Qin
Journal:  J Cell Mol Med       Date:  2014-03-14       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.